NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

NeoGenomics Reports Third Quarter 2025 Results

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

  • NeoLINK Login
  • Investors
Search
LogoNeoLINK Login
Menu
  • Home
  • Providers
    Providers
    • Oncology solutions
      • Lung cancer
      • Breast cancer
      • Colorectal cancer
      • Gastric cancer
      • Hematologic cancers
    • Pathology solutions
      • Test search
      • Lab services
    • Client support & resources
      • Certifications & licenses
      • Test requisition forms
  • Partners
    Partners
    • Biopharma services
    • Oncology data solutions
    • Regulatory support
  • Patients
  • About NeoGenomics
    About NeoGenomics
    • Who we are
    • Scientific contributions
    • Careers
    • Privacy
    • Contact us
  • Billing
    Billing
    • For clinicians
    • For patients
    • Financial assistance
    • Pay your bill online
  • Test Search
  • Investors
Test Search
Skip to main content Skip to section navigation Skip to footer
NeoGenomics, Inc. IR Overview
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report

Press Releases

Investors News & Events Press Releases
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Literature
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Info
    • Quote
    • Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • CSR
    • 2025 report
    • Inaugural Report
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Literature
  • Email Alerts
Apr 25, 2013 7:00 am EDT
NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
Apr 17, 2013 3:00 pm EDT
NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013
Feb 28, 2013 7:00 am EST
NeoGenomics Announces Pricing of $9.5 Million Public Offering
Feb 14, 2013 7:00 am EST
NeoGenomics Reports 181% Increase in Adjusted EBITDA on 38% Revenue Growth and Achieves Profitability in 2012
Feb 5, 2013 2:25 pm EST
NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February 14, 2013
Dec 17, 2012 7:00 am EST
NeoGenomics Validates and Launches NeoSITEā„¢ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 NeoGenomics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences